[{"id":"f2ce9fa4-3f0b-4aee-a86d-f80098e3eb24","acronym":"Neo PeLeMM","url":"https://clinicaltrials.gov/study/NCT05545969","created_at":"2022-09-19T13:55:47.813Z","updated_at":"2025-02-25T16:18:09.663Z","phase":"Phase 2","brief_title":"Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma","source_id_and_acronym":"NCT05545969 - Neo PeLeMM","lead_sponsor":"Melanoma Institute Australia","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2036","study_completion_date":" 05/01/2036","last_update_posted":"2024-06-26"},{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"e994ddd8-c8c2-48db-9917-ca57ceffe9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04995185","created_at":"2021-08-06T12:53:11.830Z","updated_at":"2024-07-02T16:35:03.536Z","phase":"","brief_title":"18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study","source_id_and_acronym":"NCT04995185","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" HIF1A • CA9","pipe":" | ","alterations":" HIF1A expression • VEGFA expression • CA9 expression","tags":["HIF1A • CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • VEGFA expression • CA9 expression"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 06/20/2017","start_date":" 06/20/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2024-05-15"},{"id":"323c2fcf-dd95-4448-8337-047f4cead664","acronym":"","url":"https://clinicaltrials.gov/study/NCT00866957","created_at":"2021-01-18T03:18:29.019Z","updated_at":"2024-07-02T16:35:28.771Z","phase":"","brief_title":"Human Liver Explants for HIF-1 Alpha Analysis/Comparison (HIF HCC)","source_id_and_acronym":"NCT00866957","lead_sponsor":"Northwestern University","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 02/01/2006","start_date":" 02/01/2006","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2023-11-18"},{"id":"c153810d-16f0-40f8-9439-a64b4b0d79a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332279","created_at":"2021-01-18T05:25:50.979Z","updated_at":"2024-07-02T16:35:51.525Z","phase":"Phase 1","brief_title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","source_id_and_acronym":"NCT01332279","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • HIF1A","pipe":" | ","alterations":" EGFR amplification • HIF1A expression • AKT1 amplification","tags":["EGFR • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • HIF1A expression • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • everolimus"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/01/2011","study_completion_date":" 05/01/2011","last_update_posted":"2023-04-04"},{"id":"539c3099-b137-489d-b199-cc2e1c062cbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04601961","created_at":"2021-01-19T20:30:39.168Z","updated_at":"2024-07-02T16:35:51.772Z","phase":"","brief_title":"Effects of TIVA Versus Inhalational Anaesthesia on Circulating Tumour Cells in Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT04601961","lead_sponsor":"The University of Hong Kong","biomarkers":" IL6 • TNFA • HIF1A • CRP","pipe":" | ","alterations":" HIF1A expression • IL6 expression","tags":["IL6 • TNFA • HIF1A • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression • IL6 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-03-31"},{"id":"92ea6e65-716a-48c8-97f1-b671e650d170","acronym":"","url":"https://clinicaltrials.gov/study/NCT04475705","created_at":"2021-01-18T21:29:56.966Z","updated_at":"2024-07-02T16:36:15.305Z","phase":"Phase 4","brief_title":"Propofol vs Sevo for Paediatric Tumor Surgery","source_id_and_acronym":"NCT04475705","lead_sponsor":"Hong Kong Children's Hospital","biomarkers":" IL6 • TNFA • HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["IL6 • TNFA • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/11/2021","start_date":" 01/11/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2022-03-16"},{"id":"12441980-737d-4616-9bf1-f93f67db0099","acronym":"","url":"https://clinicaltrials.gov/study/NCT01665703","created_at":"2021-01-18T07:12:01.461Z","updated_at":"2024-07-02T16:36:36.476Z","phase":"","brief_title":"Imaging Correlates of Renal Cell Carcinoma Biological Features","source_id_and_acronym":"NCT01665703","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" PBRM1 • KMT2D • HIF1A • SETD2 • MLL2","pipe":" | ","alterations":" KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression","tags":["PBRM1 • KMT2D • HIF1A • SETD2 • MLL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2D mutation • PBRM1 mutation • VHL mutation • HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2021-01-07"},{"id":"d9db1684-d818-43fa-9529-2574c116f261","acronym":"Polen","url":"https://clinicaltrials.gov/study/NCT02506816","created_at":"2021-01-18T12:06:01.875Z","updated_at":"2025-02-25T15:06:43.322Z","phase":"","brief_title":"Preoperative Olaparib Endometrial Carcinoma Study (POLEN)","source_id_and_acronym":"NCT02506816 - Polen","lead_sponsor":"MedSIR","biomarkers":" PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3","pipe":" | ","alterations":" CCND1 expression • HIF1A expression","tags":["PTEN • ARID1A • CCND1 • HIF1A • PARP1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-11-30"},{"id":"00e62920-3810-42cc-9c56-8be471703153","acronym":"","url":"https://clinicaltrials.gov/study/NCT01763931","created_at":"2021-01-18T07:45:17.102Z","updated_at":"2024-07-02T16:36:50.617Z","phase":"Phase 2","brief_title":"DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer","source_id_and_acronym":"NCT01763931","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HER-2 • ER • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2020-01-31"},{"id":"0c5c48ba-d7d3-4f6f-bfea-aa634fc92bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137627","created_at":"2021-01-18T20:12:25.557Z","updated_at":"2024-07-02T16:36:52.790Z","phase":"Phase 3","brief_title":"Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT04137627","lead_sponsor":"Indonesia University","biomarkers":" HIF1A • CD44","pipe":" | ","alterations":" CD44 expression • CD133 expression • HIF1A expression","tags":["HIF1A • CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression • CD133 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/04/2017","start_date":" 07/04/2017","primary_txt":" Primary completion: 07/30/2018","primary_completion_date":" 07/30/2018","study_txt":" Completion: 12/18/2018","study_completion_date":" 12/18/2018","last_update_posted":"2019-12-09"},{"id":"ab662527-c265-4446-8d67-67417cb82de4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01301547","created_at":"2021-01-18T05:17:28.789Z","updated_at":"2024-07-02T16:37:17.273Z","phase":"","brief_title":"Bevacizumab and Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin in Treating Patients With Refractory Solid Tumors","source_id_and_acronym":"NCT01301547","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • irinotecan • firtecan pegol (PEG-SN38)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 09/01/2011","primary_completion_date":" 09/01/2011","study_txt":"","study_completion_date":"","last_update_posted":"2017-10-06"},{"id":"fcf618c8-ddc3-495f-a4da-536faa35b9d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00117013","created_at":"2021-01-18T00:23:33.371Z","updated_at":"2024-07-02T16:37:20.382Z","phase":"Phase 1","brief_title":"A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a","source_id_and_acronym":"NCT00117013","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HIF1A","pipe":" | ","alterations":" HIF1A expression","tags":["HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e topotecan"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 06/28/2005","start_date":" 06/28/2005","primary_txt":" Primary completion: 10/25/2010","primary_completion_date":" 10/25/2010","study_txt":" Completion: 10/25/2010","study_completion_date":" 10/25/2010","last_update_posted":"2017-07-02"}]